Jubilant Pharmova shares fell after Q1 profit plunged 45% YoY to Rs 56 crore, despite revenue rising 17% to Rs 2,229 crore. The profit decline was attributed to weaker operating profitability and higher depreciation, while strong growth across segments, led by CDMO Sterile Injectables, boosted revenue.

Leave a Reply

Your email address will not be published. Required fields are marked *

Generated by Feedzy